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Curcuma longa is widely known for its anti-inflammatory activity in traditional system of medicine for centuries and has been
scientifically validated extensively.The present study was conducted to evaluate the anti-inflammatory activity of curcuminoids and
oil-free aqueous extract (COFAE) of C. longa and compare it with that of curcuminoids and turmerones (volatile oil), the bioactive
components of C. longa that are proven for the anti-inflammatory potential. The activity against inflammation was evaluated in
xylene-induced ear edema, cotton pellet granuloma models in albino Swiss mice and albino Wistar rats, respectively. The results
showed that COFAE of C. longa at three dose levels significantly (𝑃 ≤ 0.05) inhibited inflammation in both models, as evidenced
by reduction in ear weight and decrease in wet as well as dry weights of cotton pellets, when compared to the vehicle control. The
COFAE of C. longa showed considerable anti-inflammatory effects against acute and chronic inflammation and the effects were
comparable to those of curcuminoids and turmerones.
1. Introduction
Inflammation is a transitory biological response of the tissues
to harmful stimuli such as injury, exogenous and endogenous
antigens, intended to clear or eliminate the stimulus and
repair the injured tissue ultimately resulting in regeneration
and returning to homeostasis [1]. Though inflammation is a
positive defense mechanism of the body, dysregulated and
prolonged inflammatory reaction has been well recognized
as underlying cause for several disorders, namely, diabetes,
allergies, atherosclerosis, obesity, cancer, and pain. Moreover,
inflammation dysfunction leading to chronic diseases is
contributing to increased health care cost to the society [2, 3].
Nonsteroidal anti-inflammatory drugs (NSAIDs), ster-
oids, and immunosuppressant drugs that have been used
conventionally against all forms of inflammatory conditions
[4] are associated with adverse effects like ulceration, per-
foration, gastric irritation, haematochezia [5], angioedema,
hepatic failure, headache, hemolytic anemia, hyperglycemia,
osteoporosis, immunodeficiency-related problems, and oth-
ers [6]. Considering these potential adverse effects of these
drugs and their limited ability to provide long-term remis-
sion, complementary and alternative medicinal products that
are generally considered safe are continuously being explored
for their anti-inflammatory potential [7].
Curcuma longa Linn. (Turmeric) belonging to Zingiber-
aceae family has been widely used as medicine, condiment,
and cosmetic worldwide [8, 9] and valued as a functional
food because of its health promoting potentials [10]. The
rhizome of C. longa, a traditional medicine used for centuries
in the Indian subcontinent, has been scientifically vali-
dated for its antioxidant [11], antimicrobial [12], antiarthritic
[13], anticancer [14], carminative, stomachic, tonic, anal-
gesic, hemostatic [15, 16] and anti-inflammatory activities
2 Advances in Pharmacological Sciences
[17]. Most of the studies performed on C. longa focused
on curcuminoids components which comprised curcumin,
demethoxycurcumin, and bisdemethoxycurcumin [18] and
the anti-inflammatory effect of C. longa was attributed
majorly to curcumin [17] acting through the suppression
of NF-kappaB and COX-2 activation. The other bioactive
components of turmeric, namely, volatile oils, especially
turmerones, are also reported to have immunomodulatory
and anti-inflammatory activities in few of the studies [19, 20].
Albeit few reports on antiproliferative [21, 22], antidiabetic
[23] activities of curcumin-free extract of turmeric are avail-
able, anti-inflammatory potential of the same is hardly ever
reported.
Curcuminoids and turmerones extracted from C. longa
are usually used for medicinal as well as cosmetic purposes
and indeed the curcuminoids and turmerone-free compo-
nent of turmeric are often not used in the preparation of
turmeric formulations as hardly any information is available
on their bioactivity. Moreover, curcuminoids and oil-free
aqueous extract of C. longa, a spent extract, have not been yet
explored for the anti-inflammatory potential. Therefore, the
present study was designed to evaluate the anti-inflammatory
activity of COFAE of C. longa in suitable in vivo models,
keeping in view that it may help in advancing the scientific
understanding and ascertaining a better utility of the extract.
The study also focused on comparing the effect of COFAE
of C. longa with that of curcuminoids and turmerones, the
bioactive components of C. longa that are already proven for
the anti-inflammatory potential.
2. Materials and Methods
2.1. Animals. Experiments were performed on male albino
Swiss mice and albino Wistar rats of either sex bred and
reared at Central Animal Facility, Research and Devel-
opment Centre, Natural Remedies, Bangalore, India. The
animals were housed under standard laboratory conditions
of 12 h/12 h light/dark cycle at 20–24∘C and 30–70% humidity
and were provided free access to pelleted rodent feed (M/s
Gold Mohur Foods and Feeds, Bangalore, India) and UV
purified water. The animal studies were approved by the
Institutional Animal Ethics Committee.
2.2. Drugs and Chemicals. Dexamethasone and diclofenac
sodium were obtained from Cadila Healthcare (India) and
Novartis Pharma (India) respectively. Xylene was obtained
from Leonid Chemicals (India).
2.3. Plant Materials
2.3.1. Curcuminoids. Rhizomes of C. longa L. were procured
from localmarket at Bangalore, India, andwere authenticated
at the National Institute of Science Communication and
Information Resources (NISCAIR). A voucher specimen (no.
653) was deposited in the Pharmacognosy Department of
R&D Centre, Natural Remedies, Bangalore, India. Coarse
ground rhizomes (2 kg) were refluxed with ethyl acetate (8 L)
for 3 h on a water bath and filtered. The extraction procedure
was repeated two more times. The filtered extract solutions
obtained in each step were combined and concentrated by
distillation under vacuum at less than 50∘C to get a thick
paste.The latterwas further stirredwith petroleumether (1 : 3,
3 times) at room temperature and the insoluble matter was
crystallized using isopropyl alcohol to yield yellow powder of
curcuminoids (50 g).
2.3.2. COFAE of C. longa. The marc (powdered rhizomes
obtained after ethyl acetate extraction) was then extracted
with water (8 L, 3 times) at 100∘C for 3 hours and filtered.The
liquid extracts from three extraction washes were combined
and concentrated by distillation under vacuum at 70∘C to
yield a solution having 20% w/w solids. The concentrated
solutionwas then spray-dried to obtain a free flowing powder
(180 g).
2.3.3. Oil of C. longa. Coarse ground rhizomes of C. longa
(5 kg) were suspended inwater (100 L) and subjected to steam
distillation. The oil layer was separated and passed through
anhydrous sodium sulphate to get clear oil (26 mL).
2.4. Treatments Schedule. Seventy-two male albino Swiss
mice (xylene-induced ear edema model) and seventy-two
albino Wistar rats of either sex (cotton pellet granuloma
model) were randomly allotted to twelve groups, each con-
sisting of six animals. In xylene-induced ear edema model,
the control group received vehicle (water, 10mL/kg); two
other groups of mice were treated with 0.5 and 50mg/kg
body weight of dexamethasone and diclofenac, respectively,
as reference standard drugs. The remaining nine groups
received three dose levels of curcuminoids, turmerones, and
COFAE, respectively. Curcuminoids were administered at 20,
60, and 180mg/kg mice body weight, whereas turmerones
were administered at 0.05, 0.1, and 0.25mL/kg, while COFAE
at 90, 180, and 360mg/kg mice body weight were adminis-
tered.
In cotton pellet granuloma model, the control group
received vehicle (water, 10mL/kg); two other groups of rats
were treated with 0.5 and 5mg/kg bodyweight of dexametha-
sone and diclofenac, respectively, as reference standard drugs.
Curcuminoids were administered at 5, 25, and 125mg/kg rat
body weight, whereas turmerones were administered at 0.05,
0.1 and 0.15mL/kg, while COFAE at 45, 90, and 180mg/kg
rat body weight were administered to nine groups of rats.
Vehicle/reference drugs/test substances were administered by
gavage using feeding needle.
2.5. Xylene-Induced Ear Edema. The xylene-induced ear
edema test was performed as previously described [24].
Male albino Swiss mice weighing 20–30 g (6–8 weeks) were
administered with vehicle/drugs/test substances orally 1 h
prior to the xylene (50 𝜇L) application to the anterior and
posterior surfaces of the right ear topically, while left ear
served as control. After 4 h of xylene application, animal was
sacrificed; both ears were removed and ear discs of 6mm
diameter were punched out and weighed.The average weight
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difference between the right and left ear was taken as the
measure for inflammatory response.
2.6. Cotton Pellet-Induced Granuloma. Albino Wistar rats
weighing 150–180 g (6–8 weeks) were completely deprived of
food for 1 h before the vehicle/drugs/test substances admin-
istration but had free access to water. Rats were anaes-
thetized and sterile cotton pellets (10mg) were implanted
subcutaneously in axilla and groin regions of rats. The entire
procedure was carried out aseptically. Rats were adminis-
tered vehicle/drug/test substances once daily orally for seven
consecutive days. On the eighth day, cotton pellets were
meticulously dissected out and dried at 60∘C for 24 h. The
dry and wet weights of cotton pellet were measured [25]. The
percentage inhibition was calculated by using the following
formula:
Percentage inhibition = (Control − Treated)
Control
× 100. (1)
2.7. Statistical Analysis. All the valueswere expressed asmean
± SEM. The data were analyzed using one-way ANOVA
followed by post hoc Dunnett’s test. Statistical significance
was set at 𝑃 ≤ 0.05.
3. Results
3.1. Xylene-Induced Ear Edema. The average weight of the
ears and the percentage inhibition of inflammatory response
are presented in Figure 1 and Table 1, respectively. Topical
application of xylene caused an evident increase in weight
of the right ear when compared to the control left ear
in the vehicle control group, whereas the reference drugs,
dexamethasone (0.5mg/kg) and diclofenac (50mg/kg), that
served as positive controls showed significant reduction in
the average ear weight in comparison to the vehicle control.
Likewise, COFAE of C. longa at all the tested doses (90, 180,
and 360mg/kg b.w.), turmerones at the doses of 0.05 and
0.1mL/kg b.w. and curcuminoids at dose levels of 20, 60, and
180mg/kg b.w., revealed significant reduction in the average
ear weight as compared to vehicle control group.
3.2. Cotton Pellet-Induced Granuloma. The average wet and
dry weights of cotton pellets along with percentage inhibition
are summarized in Table 2.The vehicle control group showed
marked inflammatory response manifested as increase in the
wet and dry weights of the pellets. The positive controls,
namely, dexamethasone and diclofenac, showed significant
reduction in both wet and dry weights of the cotton pellets
as compared to the vehicle control. Meanwhile, COFAE of
C. longa at doses of 45, 90, and 180mg/kg exhibited significant
reduction in wet and dry weights of the cotton pellets, as
compared to the vehicle control. The percentage inhibition
in case of wet weight of pellets which was considered a
measure of inhibition of transudative and exudative phases
of inflammation was found to be 44.2, 42.6, and 36.9, respec-
tively. And the percentage inhibition in case of dry weight
of pellets which was considered a measure of inhibition of





































Values are expressed as mean ± SEM; n = 6
P ≤ 0.05
Figure 1: Effect of curcuminoids, turmerones, and COFAE on
xylene-induced ear edema in mice.
Table 1: Percentage inhibition of xylene-induced ear edema by














34.1, and 32.1, respectively. The curcuminoids at 5, 25, and
125mg/kg and turmerones at 0.05, 0.1, and 0.15mL/kg dose
levels also revealed significant reduction in wet as well as
dry weights of the cotton pellets, as compared to the vehicle
control.
4. Discussion
Complementary and alternative medicine (CAM) for the
treatment of various diseases is gaining popularity globally,
at a faster pace since the past two decades [26, 27] and the
studies revealed a worldwide market for herbal supplements
for the management of inflammatory dysfunction/diseases,
which is presently at around 83% and is expected to reach
95% in the forthcoming years [28, 29]. In Ayurveda (a
type of CAM), Curcuma has a long history of use as an
anti-inflammatory agent [30] and has been scientifically
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Table 2: Effect of curcuminoids, turmerones, and COFAE on cotton pellet-induced granuloma in rats.
Weight of cotton pellets (mg) (wet) Inhibition (%) Weight of cotton pellets (mg) (dry) Inhibition (%)
Vehicle control (10mL/kg) 228.6 ± 7.5 0 51.9 ± 1.1 0
Dexamethasone (0.5mg/kg) 101.2 ± 5.7∗ 55.7 22.7 ± 1.9∗ 56.2
Diclofenac (5mg/kg) 111.0 ± 10.4∗ 51.4 28 ± 1.7∗ 46.0
Curcuminoids (5mg/kg) 143.2 ± 7.4∗ 37.3 32 ± 2.0∗ 38.3
Curcuminoids (25mg/kg) 127.5 ± 12.4∗ 44.2 31.4 ± 0.6∗ 39.4
Curcuminoids (125mg/kg) 132.9 ± 9.6∗ 41.8 34.7 ± 1.2∗ 33.1
Turmerones (0.05mL/kg) 140.1 ± 13.5∗ 38.7 34.5 ± 1.9∗ 33.5
Turmerones (0.1mL/kg) 129.0 ± 3.7∗ 43.5 33.0 ± 1.0∗ 36.2
Turmerones (0.15mL/kg) 142.7 ± 8.6∗ 37.5 33.0 ± 0.7∗ 36.2
COFAE (45mg/kg) 127.4 ± 4.7∗ 44.2 31.7 ± 1.7∗ 38.7
COFAE (90mg/kg) 131.0 ± 6.6∗ 42.6 34.1 ± 0.9∗ 34.1
COFAE (180mg/kg) 144.2 ± 4.8∗ 36.9 35.2 ± 1.3∗ 32.1
Values are expressed as mean ± SEM; 𝑛 = 6; ∗P ≤ 0.05 treated groups versus vehicle control.
validated extensively. However, curcuminoid and oil-free
aqueous extract of C. longa have not been yet explored for
the anti-inflammatory potential and hence the present study
was designed to evaluate the anti-inflammatory activity of
COFAE of C. longa in suitable in vivo models to explore
biological activity of the extract for use. Furthermore, the
effect of COFAE of C. longa was compared with that of
curcuminoids and turmerones, the bioactive components of
C. longa that are already proven for the anti-inflammatory
potential.
Inflammation constitutes body’s response to injury and
is characterized by a series of events that mainly occur in
three distinct phases. The first phase is caused by an increase
in vascular permeability resulting in exudation of fluids
from the blood into the interstitial space; the second phase
involves the infiltration of leukocytes from the blood into
the tissue and third phase is characterized by granuloma
formation and tissue repair [31]. Therefore, it is vital to
estimate the activities of the test substance in different phases
of inflammation, while evaluating the anti-inflammatory
effect. Accordingly, COFAE of C. longa was investigated for
anti-inflammatory potential using acute exudative (xylene-
induced ear edema) and chronic proliferative (cotton pellet
granuloma) inflammation models [32–36].
Xylene-induced ear edema model is useful for the
evaluation of anti-inflammatory topical steroids and non-
steroidal antiphlogistic agents, especially those inhibiting
phospholipase A
2
[37]. Application of xylene induces acute
neurogenous edema, which is partially associated with the
substance P. Substance P is widely distributed in the central
and peripheral nervous system and its release from sensory
neurons in the periphery causes vasodilatation and plasma
extravasations leading to swelling of the ear, suggesting the
role of xylene in neurogenous inflammation [38]. Moreover,
the ear edema associated with xylene involves inflammatory
mediators such as histamine, kinin, and fibrinolysin [39].The
COFAE of C. longa in the present study exhibited significant
activity to counter the acute inflammation in the xylene-
induced ear edema and the effect was comparable to that
of curcuminoids and turmerones. The significant inhibition
of xylene-induced ear swelling in mice treated with COFAE
of C. longa provides a probability that the active principles
in the extract could reduce the release of substance P or
other inflammatory mediators such as histamine, kinin and
fibrinolysin or antagonize the actions.
Chronic inflammation is the reaction arising when the
acute response is insufficient to eliminate the proinflamma-
tory agents. Chronic inflammation includes proliferation of
fibroblasts and infiltration of neutrophils with exudation of
fluid. It occurs by means of development of proliferative cells
which can either spread or form granuloma [40]. Cotton
pellet granuloma model has been widely used to evaluate
the transudative, exudative, and proliferative components of
chronic inflammation. Transudate phase causes increase in
the wet weight of the cotton pellet while hosting inflamma-
tory response to the implanted cotton pellet between 3 and 6
days causes granuloma formation. Therefore, increase in dry
weight is considered as a measure of proliferative component
of inflammation [41–43].
In the present study, the wet and the dry weights of
the pellets, which correlate with transudative and prolif-
erative (granuloma tissue) components of inflammation,
were significantly inhibited by COFAE of Curcuma and
the effect was equivalent to that of curcuminoids and tur-
merones. Nevertheless, turmerones showed marginally less
anti-inflammatory activity compared to curcuminoids. This
reduction in transudate and granuloma formation by COFAE
ofC. longa administrationmay be correlatedwith its ability to
reduce the number of fibroblasts and the synthesis of collagen
and mucopolysaccharides that are involved in the formation
of granuloma tissue [44–46].
C. longa comprises a group of three curcuminoids such
as curcumin (diferuloylmethane), demethoxycurcumin, and
bisdemethoxycurcumin, as well as volatile oils (turmerone,
atlantone, and zingiberene), sugars, proteins, and resins
[17]. Yegnanarayan et al. [47] demonstrated significant
anti-inflammatory effect of C. longa extracts obtained by
petroleum ether, 50% alcohol, and water in both exudative
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and proliferative inflammation. Subsequently, the extensive
research on C. longa and curcuminoids specifically on cur-
cumin in the past two decades thoroughly established their
anti-inflammatory potential and are reported to downreg-
ulate the activity of cyclooxygenase-2 (COX-2), lipoxyge-
nase, and inducible nitric oxide synthase (iNOS) enzymes;
inhibit the production of the inflammatory cytokines tumor
necrosis factor-alpha (TNF-𝛼), interleukins (IL) 1, 2, 6,
8, and 12, monocyte chemoattractant protein (MCP), and
migration inhibitory protein; and downregulate mitogen-
activated and Janus kinases [17, 48, 49]. Likewise, Funk
et al. and Liju et al. have elucidated the anti-inflammatory
effects of turmeric essential oils on acute and chronic
inflammatory models and suggested an inhibitory effect
on release of inflammatory mediators such as histamine,
bradykinin, 5-hydroxytryptamine, and prostaglandins as the
mode of action. The present study clearly reinstated the anti-
inflammatory potential of curcuminoids and turmerones in
both acute and chronic inflammatory models.
Curcuminoids and turmerones are usually used for
medicinal as well as cosmetic purposes and indeed the
COFAE of turmeric is often not used in the preparation of
turmeric formulations. Consequently, the present study on
COFAE of C. longa revealed significant anti-inflammatory
potential in both acute exudative and chronic proliferative
inflammation models, signifying the presence of bioactive
principles in the extract, capable of producing the anti-
inflammatory effect.
The whole C. longa extract encompasses curcuminoids,
volatile oils, andwater soluble polysaccharides [50].However,
very few pharmacological studies are available regarding the
polysaccharides of Curcuma species. A group of polysaccha-
rides isolated from C. longa, named ukonan A, B, C, and D,
have shown reticuloendothelial system-potentiating activity
and anticomplementary activities [51]. Polysaccharides iso-
lated from related species C. zedoaria and C. xanthorrhiza
have been shown to have macrophage-stimulating activity
via specific activation of NF-𝜅B [52, 53]. Moreover, recent
reports available on polysaccharides from different natural
sources indicated their role as free radical scavengers and
antioxidants, which has been suggested as the pharmacolog-
ical basis for prevention of inflammation and atherosclerosis
by polysaccharides [54]. Also clinical trial by Madhu et al.,
[55] that evaluated the efficacy of Curcuma longa contain-
ing polysaccharides in osteoarthritis patients, indicates the
involvement of polysaccharides against inflammation [55].
Hence, the anti-inflammatory effect obtained after COFAE
of C. longa treatment could be correlated with the presence
of polysaccharides and/or any other unexplored active prin-
ciples. Consequently, there is a definite need for detailed
experimental studies to define the precise mechanism of
action of COFAE of C. longa and to have an elaborative
phytochemical study to elucidate the active molecule(s)
responsible for the therapeutic effect.
In conclusion, the present study demonstrated potent
anti-inflammatory activity of COFAE of C. longa, even
comparable to that of the proven anti-inflammatory bioac-
tive components of Curcuma, namely, curcuminoids and
turmerones, in both acute exudative (xylene induced ear
edema) and chronic proliferative (cotton pellet granuloma)
inflammation models, thereby indicating the possibility of
developing COFAE of C. longa as a safe and potent anti-
inflammatory substance.
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